clinical trial · NCT07338786
A Phase I Clinical Trial to Evaluate the Safety of Different Immunization Schedules of a Lyophilized Human Rabies Vaccine (Human Diploid Cell)
Changchun BCHT Biotechnology Co.·phase1·enrolling by invitation·n = 80
RabiesPreventionLyophilized Human Rabies Vaccine (Human Diploid Cell)
brief summary
This clinical trial employed a single-center, open-label, single-arm design. A total of 80 participants aged 10 to 60 years were enrolled and divided into two age groups: 40 in the 18-60 years cohort and 40 in the 10-17 years cohort. All participants received the lyophilized human rabies vaccine (human diploid cell)
started
Sep 13, 2025
primary completion
Jan 4, 2026
completion
May 1, 2026
last updated
Jan 14, 2026
official title
A Single-Center, Open-Label, Single-Arm, Phase I Clinical Trial to Evaluate the Safety of a Lyophilized Human Rabies Vaccine (Human Diploid Cell) Administered in Different Immunization Schedules.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol